You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Combined treatment with HMGN1 and anti-CD4 depleting antibody reverses T cell exhaustion and exerts robust anti-tumor effects in mice

Fig. 1

HMGN1/αCD4 treatment exerted robust anti-tumor effects in mice. a The optimized protocol for HMGN1/αCD4 treatment in Colon26 model. b The effective dose of murine HMGN1 (mH) in combination with anti-CD4 depleting antibody (αCD4) was screened within a range of 0.0032 to 2 μg/mL mH. #, P < 0.05, ##, P < 0.01, ###, P < 0.001 for a Student’s t-test comparing mH/αCD4 and αCD4-treated groups at day 29. c The tumor growth analysis during mH/αCD4 treatment, and the tumor volume of each mice on day 18. d The tumor progression analysis for 40 days. e Tumor rechallenge analysis. f The tumor growth analysis during mH/αCD4 treatment in Colon26-bearing BALB/c-nu model, and the tumor volume of each mice on day 18. Tumor growth is representative of three independent experiments with at least eight mice per group. Data are presented as mean ± SEM. *, P < 0.05, **, P < 0.01, ***, P < 0.001 for a dunnett’s post hoc test (compared with control); p values in the figure indicate Student’s t-test comparing mH/αCD4-treated and αCD4-treated groups

Back to article page